Testing menstrual blood for human papillomavirus (HPV) could be a "robust alternative or replacement" for current cervical ...

A study by researchers at Federal University Teaching Hospital, Lafia, has found that marital status does not significantly influence the risk of Human Papillomavirus infection or cervical dysplasia ...

Share on Pinterest What do the new cervical cancer screening guidelines say? We outline three key changes. Image credit: Maria Korneeva/Getty Images On December 4, the American Cancer Society (ACS) ...

The HPV vaccine is very safe and highly effective at preventing cervical cancer, according to two large reviews that support routinely vaccinating adolescents against human papillomavirus. HPV is the ...

Introduction: High-grade squamous intraepithelial lesions (HSIL), such as cervical intraepithelial neoplasia grade 3 (CIN3), are precursors to invasive cancer. Although cancer develops in only 1–2 out ...

Stage 2 cervical cancer is classified into 2A and 2B, based on tumor spread and size, affecting treatment decisions. Diagnosis involves biopsies and imaging tests, including CT, MRI, and PET scans, to ...

This study reports important new insights into the roles of a long noncoding RNA, lnc-FANCI-2, in the progression of cervical cancer induced by a type of human papillomavirus. Through a blend of cell ...

Background: Coexistent cervical intraepithelial neoplasia (CIN) and vaginal intraepithelial neoplasia (VaIN) is problematic, posing challenges for patient management. This study focused on the ...

A meta-analysis of induction chemotherapy (ICT) followed by chemoradiotherapy for locally advanced cervical cancer: The role of ICT type and duration on efficacy outcomes. This is an ASCO Meeting ...

Please provide your email address to receive an email when new articles are posted on . Only 45.5% of women treated for high-grade cervical dysplasia completed two surveillance co-tests within 30 ...

Among women ages 20-24 who were screened from 2008-2022, cervical precancer rates decreased by about 80%. Among women ages 25-29, CIN3+ rates decreased by 37%. These data support vaccinating children ...

DARE-HPV is a proposed treatment for HPV-related cervical diseases, supported by up to $2 million in NIAID grants. Daré Bioscience, Inc. has announced the development of DARE-HPV, an investigational ...